

References on Espinheira Santa from Part 3 of [Fighting Cancer with Plants from the Rainforest](#) By Leslie Taylor

The published research referenced in the book which is shown below will include the initials **HS**, **IVT**, **IVA**, **REV**, **INS**, **REV** and **NEW**. HS refers to research conducted in humans; IVT refers to *in vitro* research conducted inside of test tubes; IVA refers to *in vivo* research conducted in animals; REV refers to a review article that evaluated and summarizes multiple studies on the subject; INS refers to *in silico* research (newer computer modeling including molecular docking studies) and NEW refers new biological research methods which determine genes and signaling pathways, and molecular pathways of actions which were developed during and after the Human Genome Project discussed in chapter 4.

This research below was last updated in July 2025. To view research published after that time, follow these links to the National Institute of Health's National Library of Medicine on [espinheira santa](#), [pristimerin](#), [maytenin](#), [tingenone](#), [friedelin](#), [celastrol](#) and [maytansine](#).

Reviews

Prabhu. K., et al. "Anticancer potential and molecular targets of pristimerin in human malignancies." *Pharmaceuticals* (Basel). 2024 Apr; 17(5): 578. [[Free Article](#)] (REV)

Huong D., et al. "Pristimerin: natural occurrence, biosynthesis, pharmacology, and pharmacokinetics." *Rev. Bras. Farmacogn.* 2024; 34: 467–480. (REV)

Mathur, A., et al. "Regulating pri/pre-microRNA up/down expressed in cancer proliferation, angiogenesis and metastasis using selected potent triterpenoids. Pt 1." *Int. J. Biol. Macromol.* 2024; 257: 127945. (REV)

Sun, J., et al. "Pristimerin exerts pharmacological effects through multiple signaling pathways: A comprehensive review." *Drug Des. Dev. Ther.* 2024 May; 18: 1673-1694. [[Free Article](#)] (REV)

Carrillo-Martinez, E., "Quercetin, a flavonoid with great pharmacological capacity." *Molecules.* 2024 Feb; 29(5): 1000. [[Free Article](#)] (REV)

Rahmani, A., et al. "Myricetin: A significant emphasis on its anticancer potential via the modulation of inflammation and signal transduction pathways." *Int. J. Mol. Sci.* 2023 Jun; 24(11): 9665. [[Free Article](#)] (REV)

Qattan, M., et al. "Therapeutic importance of kaempferol in the treatment of cancer through the modulation of cell signalling pathways." *Molecules.* 2022 Dec; 27 (24): 8864. [[Free Article](#)] (REV)

Farhan, M. "Green tea catechins: Nature's way of preventing and treating cancer." *Int. J. Mol. Sci.* 2022 Sep; 23(18): 10713. [[Free Article](#)] (REV)

Chen, R., et al. "Cellular and molecular mechanisms of pristimerin in cancer therapy: Recent advances." *Front. Oncol.* 2021 May; 11: 671548. [[Free Article](#)] (REV)

Wang, Y., et al. "The multifaceted mechanisms of pristimerin in the treatment of tumors state-of-the-art." *Biomed. Pharma.* 2022; 154: 113575. (REV)

Chen, R., et al. "Cellular and molecular mechanisms of pristimerin in cancer therapy: Recent advances." *Front. Oncol.* 2021; 11: 671548. [[Free Article](#)] (REV)

Li, J. et al. "Anti-cancer effects of pristimerin and the mechanisms: A critical review." *Front. Pharmacol.* 2019; 10: 746. [[Free Article](#)] (REV)

Yousef, B., et al. "Anticancer potential and molecular targets of pristimerin: A mini-review." *Curr. Cancer Drug Targets.* 2017; 17(2): 100-108. (REV)

Gomez, J., et al. "Antitumoral, mutagenic and (anti)estrogenic activities of tingenone and pristimerin." *Rev. Bras. Farmacogn.* 2011 Dec; 21(6): 963-971. [[Free Article](#)] (REV)

Yadav, V., et al. "Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer." *Toxins* (Basel). 2010 Oct; 2(10): 2428-66. [[Free Article](#)] (REV)

Santos-Oliveira, R. et al. "Review of *Maytenus ilicifolia* Mart. Ex Reissek, Celastraceae. Contribution to the studies of pharmacological properties." *Braz. J. Pharmacogn.* 2009; 19: 650-659. (REV)

Petronelli, A., et al. "Triterpenoids as new promising anticancer drugs." *Anticancer Drugs.* 2009 Nov; 20(10): 880-92. (REV)

Cassady, J., et al. "Recent developments in the maytansinoids antitumor agents." *Chem. Pharm. Bull.* 2004; 52(1): 1-26. (REV)

Test Tube Research on Multiple Cancer Cell Lines:

Bukhari, S., et al. "Effects of plants and isolates of Celastraceae family on cancer pathways." *Anticancer Agents Med. Chem.* 2015; 15(6): 681-93. (REV)

Ohsaki, A., et al. "Four new triterpenoids from *Maytenus ilicifolia*." *J. Nat. Prod.* 2004; 67(3): 469-71. (IVT)

Horn, R. C., et al. "Antimutagenic activity of extracts of natural substances in the Salmonella/microsome assay." *Mutagenesis.* 2003 Mar; 18(2): 113-8. (IVT)

Buffa Filho, W., et al. "Quantitative determination for cytotoxic Friedo-nor-oleanane derivatives from five morphological types of *Maytenus ilicifolia* (Celastraceae) by reverse-phase high-performance liquid chromatography." *Phytochem. Anal.* 2002 Mar-Apr; 13(2): 75-8. (IVT)

Chávez, H., et al. "Structure of new bioactive triterpenes related to 22- β -hydroxy-tingenone." *Tetrahedron.* 1998; 54: 13579–13590. (IVT)

Shirota, O., et al. "Cytotoxic aromatic triterpenes from *Maytenus ilicifolia* and *Maytenus chuchuhuasca*." *J. Nat. Prod.* 1994; 57(12): 1675-81. (IVT)

Itokawa, H., et al. "Cangorins F-J, five additional oligo-nicotinated sesquiterpene polyesters from *Maytenus ilicifolia*." *J. Nat. Prod.* 1994; 57(4): 460-70. (IVT)

Arisawa, M., et al. "Cell growth inhibition of KB cells by plant extracts." *Natural Med.* 1994; 48(4): 338-347. (IVT)

Itokawa, H., et al. "Oligo-nicotinated sesquiterpene polyesters from *Maytenus ilicifolia*." *J. Nat. Prod.* 1993; 56(9): 1479-1485. (IVT)

Itokawa, H., et al. "Antitumor substances from South American plants." *Pharmacobio. Dyn.* 1992; 15(1): S. (IVT)

Nozaki, H., et al. "Antitumour triterpenes of *Maytenus diversifolia*." *J. Phytochem.* 1986; 25(2): 479-485. (IVT)

Wolpert-Defillipes, M., et al. "Initial studies on the cytotoxic action of maytansine, a novel ansa macrolide." *Biochemical Pharmacology.* 1975; 24: 751-54. (IVT)

Monache, F. D., et al., "Maitenin: A new antitumoral substance from *Maytenus sp.*" *Gazetta Chimica Italiana* 1972; 102: 317-20. (IVT)

Biliary Tract & Gastric Cancers

Sun, J., et al. "Induction of cell-cycle arrest and apoptosis in human cholangiocarcinoma cells by pristimerin." *J. Cell Biochem.* 2019; 120(7): 12002-12009. (IVT, IVA, INS, NEW)

Zhao, F., et al. "Pristimerin inhibits growth and induces apoptosis of gastric cancer MGC803 and SGC7901 cells." *World Chin. J. Dig.* 2016; 24(07): 1064-1069. (IVT)

Bone Cancer

Mori, Y., et al. "Antitumor effects of pristimerin on human osteosarcoma cells *in vitro* and *in vivo*." *Onco. Targets Ther.* 2017 Nov; 10: 5703-5710. (IVT, IVA, NEW)

Brain Cancer

Zhang, X., et al. "A detailed evaluation of the advantages among extracellular vesicles from three cell origins for targeting delivery of celastrol and treatment of glioblastoma." *Int. J. Pharm.* 2024 Dec; 25: 667 (Pt B): 125005. (IVT, IVA, INS, NEW)

Li, Z., et al. "Pristimerin inhibits glioma progression by targeting AGO2 and PTPN1 expression via miR-542-5p." *Biosci. Rep.* 2019; 39: BSR20182389. (INS, NEW)

Zhao, H., et al. "Pristimerin triggers AIF-dependent programmed necrosis in glioma cells via activation of JNK." *Cancer Lett.* 2016 Apr; 374(1): 136-148. (IVT, IVA, INS, NEW)

Yan, Y., et al. "The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen species-mediated mitochondrial dysfunction." *Oncol. Lett.* 2013 Jan; 5(1): 242-248. (IVT, NEW)

Breast Cancer

Liu, Q., et al. "Pristimerin promotes ubiquitination of HSPA8 and activates the VAV1/ERK pathway to suppress TNBC proliferation." *Adv. Sci. (Weinh).* 2025 Mar;1 2(10): e2413174.

Liu, S., et al. "Pristimerin exerts antitumor activity against MDA-MB-231 triple-negative breast cancer cells by reversing of epithelial-mesenchymal transition via downregulation of integrin $\beta 3$." *Biomed. J.* 2020 Dec; 44(6), Supplement 1: S84-S92. (IVT, NEW)

Cheng S., et al. "Pristimerin suppressed breast cancer progression via miR-542-5p/DUB3 axis." *Onco. Targets Ther.* 2020; 13: 6651–6660. (IVT, INS, NEW)

Zhao, Q., et al. "Pristimerin induces apoptosis and autophagy via activation of ROS/ASK1/JNK pathway in human breast cancer *in vitro* and *in vivo*." *Cell Death Discov.* 2019; 5: 125. (IVT, IVA, NEW)

Cevatemre, B., et al. "A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells *in vitro* and xenografts *in vivo* through apoptosis and an incomplete autophagy in breast cancer." *Pharmacol. Res.* 2018 Mar; 129: 500-514. (IVT, IVA, NEW)

Subash-Babu, P., et al. "In vitro cytotoxic potential of friedelin in human MCF-7 breast cancer cell: Regulate early expression of Cdkn2a and pRb1, neutralize mdm2-p53 amalgamation and functional stabilization of p53." *Exp. Toxicol. Pathol.* 2017; 69: 630–636. (IVT, INS, NEW)

Xie, G., et al. "Effect of pristimerin on the growth and apoptosis of MCF-7 breast cancer cells and the mechanism." *J. Dalian Med. Univ.* 2016; 38(03): 215-218. (IVT, NEW)

Xie, G., et al. "Inhibitory effect of pristimerin on growth of taxol-resistant breast cancer cells." *J. Guizhou Med. Univ.* 2016; 41(09): 1029-1032. (IVT, NEW)

Lee J. et al. "Anticancer activity of pristimerin in epidermal growth factor receptor 2-positive SKBR3 human breast cancer cells." *Biol. Pharm. Bull.* 2013; 36: 316–325. **(IVT NEW)**

Mu, X., et al. "Pristimerin inhibits breast cancer cell migration by up- regulating regulator of G protein signaling 4 expression." *Asian Pac. J. Cancer Prev.* 2012; 13(4): 1097-104. **(IVT, IVA, NEW)**

Mu, X., et al. "Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation." *Molecules.* 2012 Jun; 17(6): 6854-68. **(IVT, IVA, NEW)**

Cevatemre, B., et al. "A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells *in vitro* and xenografts *in vivo* through apoptosis and an incomplete autophagy in breast cancer." *Pharmacol.Res.* 2018; 129: m500–514. **(IVT, IVA, NEW)**

Wu, C. et al. "Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria." *Mol. Cancer Ther.* 2005; 4: 1277–1285. **(IVT, NEW)**

Cervical Cancer

Eum D., et al. "Triterpenoid pristimerin synergizes with taxol to induce cervical cancer cell death through reactive oxygen species-mediated mitochondrial dysfunction." *Anticancer Drugs.* 2011; 22: 763–773. **(IVA, IVT)**

Byun, J., et al. "Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells." *Mol. Pharmacol.* 2009 Oct; 76(4): 734-44. **(IVT, INS, NEW)**

Colorectal Cancer

Zhao, Q., et al. "Effect of pristimerin on apoptosis through activation of ROS/endoplasmic reticulum (ER) stress-mediated noxa in colorectal cancer." *Phytomedicine.* 2021; 80: 153399. **(IVT, IVA, NEW)**

Zhao Q., et al. "Pristimerin suppresses colorectal cancer through inhibiting inflammatory responses and Wnt/beta-catenin signaling." *Toxicol. Appl. Pharmacol.* 2020; 386: 114813. **(IVT, IVA, NEW)**

Yousef B., et al. "Pristimerin exhibits *in vitro* and *in vivo* anticancer activities through inhibition of nuclear factor-small ka, Cyrillic B signaling pathway in colorectal cancer cells." *Phytomedicine.* 2018; 40: 140–147. **(IVT, IVA, NEW)**

Park J., and Kim, J. "Pristimerin, a naturally occurring triterpenoid, attenuates tumorigenesis in experimental colitis-associated colon cancer." *Phytomedicine.* 2018 Mar; 42: 164-171. **(IVT, IVA, NEW)**

Yousef, B., et al. "Pristimerin demonstrates anticancer potential in colorectal cancer cells by inducing G1 phase arrest and apoptosis and suppressing various pro-survival signaling proteins." *Oncol. Rep.* 2016 Feb; 35(2): 1091-100. **(IVT, INS, NEW)**

Yousef, B., et al. "Pristimerin inhibits proliferation, migration and invasion, and induces apoptosis in HCT-116 colorectal cancer cells." *Biomed. Pharmacother.* 2016 Apr; 79: 112-119. **(IVT, IVA, NEW)**

Araújo Júnior, R., "Maytenus ilicifolia dry extract protects normal cells, induces apoptosis and regulates Bcl-2 in human cancer cells." *Exp. Biol. Med.* 2013 Nov; 238(11): 1251-1258. **(IVT)**

Liu, C., et al. "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids." *Proc. Natl. Acad. Sci.* 1996 Aug; 93(16): 8618-8623. **(IVA)**

Fibrosarcoma

Hayashi, D., et al. "Pristimerin inhibits the proliferation of HT1080 fibrosarcoma cells by inducing apoptosis." *Oncol. Lett.* 2020; 19: 2963–2970. **(IVT, IVA, NEW)**

Head and Neck Cancers

Feng, M., et al. "Pristimerin induces Noxa-dependent apoptosis by activating the FoxO3a pathway in esophageal squamous cell carcinoma." *Chin. J. Nat. Med.* 2025 May; 23(5): 585-592.

Wang, Y., et al. "[Pristimerin enhances cisplatin-induced apoptosis in nasopharyngeal carcinoma cells via ROS-mediated deactivation of the PI3K/AKT signaling pathway]." *Nan. Fang. Yi. Ke. Da. Xue. Xue. Bao.* 2024 May; 44(5): 904-912. **(IVT, NEW)**

Hu, W., et al. "Pristimerin exhibits anti-cancer activity by inducing ER stress and AKT/GSK3beta pathway through increasing intracellular ROS production in human esophageal cancer cells." *Toxicol. In Vitro.* 2024 Aug; 99: 105867. **(IVT, NEW)**

Zhao, Q., et al. "Pristimerin induces apoptosis and tumor inhibition of oral squamous cell carcinoma through activating ROS-dependent ER stress/Noxa pathway." *Phytomedicine.* 2021 Nov; 92: 153723. **(IVA, IVT)**

Hernandes, C., et al., "Anticancer activities of the quinone-methide triterpenes maytenin and 22- β -hydroxymaytenin obtained from cultivated *Maytenus ilicifolia* roots associated with down-regulation of miRNA-27a and miR-20a/miR-17-5p." *Molecules.* 2020 Feb; 25(3): 760. **(IVT, IVA, NEW)**

Huang, P., et al. "A hopeful natural product, pristimerin, induces apoptosis, cell cycle arrest, and autophagy in esophageal cancer cells." *Anal. Cell. Pathol.* 2019; 14: 6127169. **(IVT, IVA, NEW)**

Wu, H., et al. "Pristimerin induces apoptosis of oral squamous cell carcinoma cells via G1 phase arrest and MAPK/Erk1/2 and Akt signaling inhibition." *Oncol Lett.* 2019 Mar; 17(3): 3017-3025.

Tu, Y., et al. "Pristimerin targeting NF- κ B pathway inhibits proliferation, migration, and invasion in esophageal squamous cell carcinoma cells." *Cell. Biochem. Funct.* 2018 Jun; 36(4): 228-240.

Leukemia

Kundu, S., et al. "Anti-leukemic attributes of natural compounds targeting autophagy: A closer look into the molecular mechanisms." *Nutr. Cancer.* 2024; 76(3): 236-251.

Rodrigues, A., et al. "Tingenone and 22-hydroxytingenone target oxidative stress through downregulation of thioredoxin, leading to DNA double-strand break and JNK/p38-mediated apoptosis in acute myeloid leukemia HL-60 cells." *Biomed. Pharmacother.* 2021 Oct; 142: 112034. **(IVT, NEW)**

Chang, W., et al. "Friedelin inhibits the growth and metastasis of human leukemia cells via modulation of MEK/ERK and PI3K/AKT signaling pathways." *J. BUON.* (Official Journal of the Balkan Union of Oncology). 2020 May-Jun; 25(3): 1594-1599. **(IVT, NEW)**

Liu Y., et al. "Pristimerin induces autophagy-mediated cell death in K562 cells through the ROS/JNK signaling pathway." *Chem. Biodivers.* 2019; 16: e1900325. **(IVT, NEW)**

Lu, Z., et al. "Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF- κ B signaling and depleting Bcr-Abl." *Mol. Cancer.* 2010 May 19; 9: 112. **(IVT, IVA, NEW)**

Costa, P., et al. "Antiproliferative activity of pristimerin isolated from *Maytenus ilicifolia* (Celastraceae) in human HL-60 cells." *Toxicol. In Vitro.* 2008 Jun; 22(4): 854-63. **(IVT)**

Nakao, H., et al. "Cytotoxic activity of maytanprine isolated from *Maytenus diversifolia* in human leukemia K562 cells." *Biol. Pharm. Bull.* 2004; 27(8): 1236-40. **(IVT)**

Liver Cancer

- Tang, Y., et al. "Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27kip1 signaling pathway." *Phytomedicine*. 2021; 86: 153563. **(IVT, NEW)**
- Araújo Júnior, R., "Maytenus ilicifolia dry extract protects normal cells, induces apoptosis and regulates Bcl-2 in human cancer cells." *Exp. Biol. Med.* 2013 Nov; 238(11): 1251-8. **(IVT)**
- Guo, Y., et al. "Triterpenoid pristimerin induced HepG2 cells apoptosis through ROS-mediated mitochondrial dysfunction." *J. BUON*. 2013 Apr-Jun; 18(2): 477-85. **(IVT, NEW)**

Lung Cancer

- Zhao, Z., et al. "Celastrol elicits antitumor effects by inhibiting the STAT3 pathway through ROS accumulation in non-small cell lung cancer." *J. Transl. Med.* 2022 Nov; 20(1): 525. **(IVT, NEW)**
- Wu, L., et al. "Regulation of pristimerin on proliferation and mitochondrial membrane potential of non-small cell lung cancer." *J. Beihua Univ. (Nat. Sci.)*, 2021; 22 (03): 319-323. **(IVT, NEW)**
- Chai, H., et al. "Pristimerin inhibiting the invasion and migration of lung cancer A549 cells by down-regulating integrin $\beta 1$." *China Pharm.* 2021; 24(08): 445-449. **(IVT, NEW)**
- Lei, X., "Identification of a novel tumor angiogenesis inhibitor targeting Shh/Gli1 signaling pathway in non-small cell lung cancer." *Cell Death Dis.* 2020; 11: 232. **(IVA, IVT, NEW)**
- Li, J., et al. "Pristimerin induces apoptosis and inhibits proliferation, migration in H1299 lung cancer cells." *J. Cancer*. 2020; 11(21): 6348-6355. **(IVT, NEW)**
- Tang, Y., et al. "Pristimerin exacerbates cellular injury in conditionally reprogrammed patient-derived lung adenocarcinoma cells by aggravating mitochondrial impairment and endoplasmic reticulum stress through EphB4/CDC42/N-WASP signaling." *Oxid. Med. Cell. Longev.* 2020: 7409853. **(IVT, NEW)**
- Lei, X., et al. "Effect and underlying mechanism of pristimerin on migration and invasion of NCI-H1299 cells." *Shanghai J. Tradit. Chin. Med.* 2020; 54(12): 12254. **(IVT, IVA, NEW)**
- Zhang, Y., et al. "Pristimerin enhances the effect of cisplatin by inhibiting the miR 23a/Akt/GSK3 β signaling pathway and suppressing autophagy in lung cancer cells." *Int. J. Mol. Med.* 2019 Mar; 43(3): 1382-1394. **(IVT, NEW)**
- Lu, Z., et al. "Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF- κ B signaling and depleting Bcr-Abl." *Molecular Cancer*. 2010; 9(1): 112. **(IVT, IVA, NEW)**

Multiple Myeloma

- Almaghrbi, H., et al. "Analysis of signaling cascades from myeloma cells treated with pristimerin." *Adv. Protein Chem. Struct. Biol.* 2023; 134: 147-174. **(IVT, NEW)**
- Jöhrer, K., et al. "Multiple myeloma inhibitory activity of plant natural products." *Cancers (Basel)*. 2021 May; 13(11): 2678. **(REV)**
- Tiedemann, R., et al. "Identification of a potent natural triterpenoid inhibitor of proteasome chymotrypsin-like activity and NF-kappaB with antimyeloma activity *in vitro* and *in vivo*." *Blood*. 2009 Apr; 113(17): 4027-37. **(IVT, IVA, NEW)**

Ovarian Cancer

Gao, X., et al. "Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of pro-survival Akt/NF- κ B/mTOR signaling." *J. Exp. Ther. Oncol.* 2014; 10(4): 275-83. **(IVT, NEW)**

Pancreatic Cancer

Jiang, Z., et al. "Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells." *Food Chem. Toxicol.* 2021; 147: 111919. **(IVT, NEW)**

Deeb, D., et al. "Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells." *Oncol. Rep.* 2015 Jul; 34(1): 518-24. **(IVT, NEW)**

Deeb, D., et al. "Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-kappaB/mTOR signaling proteins and anti-apoptotic Bcl-2." *Int. J. Oncol.* 2014; 44: 1707–1715. **(IVT, NEW)**

Wang, Y., et al. "Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells." *PLoS One.* 2012; 7(8): e43826. **(IVT, NEW)**

Prostate Cancer

Xu, H., et al. "Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1." *Signal Transduct. Target Ther.* 2023 Feb; 8(1): 51. **(IVT, INS, IVA, NEW)**

Lee, S., et al. "Anti-cancer effect of pristimerin by inhibition of HIF-1 α involves the SPHK-1 pathway in hypoxic prostate cancer cells." *BMC Cancer.* 2016 Aug; 16: 701. **(IVT, NEW)**

Huang, S., et al. "Pristimerin inhibits prostate cancer bone metastasis by targeting PC-3 stem cell characteristics and VEGF-induced vasculogenesis of BM-EPCs." *Cell. Physiol. Biochem.* 2015; 37(1): 253-68. **(IVT, IVA, NEW)**

Liu Y., et al. "Role of telomerase in anticancer activity of pristimerin in prostate cancer cells." *J. Exp. Ther. Oncol.* 2015; 11: 41–49. **(IVT, NEW)**

Liu, Y., et al. "Ubiquitin-proteasomal degradation of antiapoptotic survivin facilitates induction of apoptosis in prostate cancer cells by pristimerin." *Int. J. Oncol.* 2014 Oct; 45(4): 1735-41. **(IVT, NEW)**

Liu, Y., et al. "Pristimerin induces apoptosis in prostate cancer cells by down-regulating Bcl-2 through ROS-dependent ubiquitin-proteasomal degradation pathway." *J. Carcinog. Mutagen.* 2013 Nov 5; Suppl 6: 005. **(IVT, NEW)**

Yang, H., et al. "Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells." *J. Cell Biochem.* 2008; 103: 234–244. **(IVT, NEW)**

Skin Cancer and Melanoma

Al-Tamimi, M., et al. "Pristimerin mediated anticancer effects and sensitization of human skin cancer cells through modulation of MAPK signaling pathways." *Biomed. Pharmacother.* 2022; 156: 113950. **(IVT, NEW)**

Xie, X., et al. "Pristimerin attenuates cell proliferation of uveal melanoma cells by inhibiting insulin-like growth factor-1 receptor and its downstream pathways." *J. Cell. Mol. Med.* 2019 Nov; 23(11): 7545-7553.

Zhang, B., et al. "Pristimerin effectively inhibits the malignant phenotypes of uveal melanoma cells by targeting NF κ B pathway." *Int. J. Oncol.* 2017 Sep; 51(3): 887-898. **(IVT, NEW)**

Melo, A. M., et al. "First observations on the topical use of primin, plumbagin and maytenin in patients with skin cancer." *Rev. Inst. Antibiot.* 1974 Dec. **(IVA, IVT)**

Reducing chemotherapy drug side effects:

- Lu, Y., et al. "Pristimerin protects against pathological cardiac hypertrophy through improvement of PPAR α pathway." *Toxicol. Appl. Pharmacol.* 2023 Aug; 473(15): 116572. (IVA, IVT, NEW)
- Yarmohammadi, F., et al. "Natural compounds against doxorubicin-induced cardiotoxicity: A review on the involvement of Nrf2/ARE signaling pathway." *Phytother. Res.* 2021 Mar; 35(3): 1163-1175.
- El-Agamy, D., et al. "Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways." *Cancer Manag. Res.* 2018 Dec; 11: 47-61. (IVA, NEW)
- Kasse, C., et al. "The use of *Maytenus ilicifolia* to prevent cisplatin-induced ototoxicity." *Braz. J. Otorhinolaryngol.* 2008 Sep-Oct; 74(5): 712-717. (IVA, NEW)

Enhancing chemotherapy drug effectiveness and/or overcoming drug resistance:

- Wang, Y., et al. "[Pristimerin enhances cisplatin-induced apoptosis in nasopharyngeal carcinoma cells via ROS-mediated deactivation of the PI3K/AKT signaling pathway]." *Nan. Fang. Yi. Ke. Da. Xue. Xue. Bao.* 2024 May; 44(5): 904-912. (IVT, NEW)
- Moreira, H., et al. "Genotoxic and anti-migratory effects of camptothecin combined with celastrol or resveratrol in metastatic and stem-like cells of colon cancer." *Cancers (Basel).* 2024 Sep; 16(19): 3279. (IVT, NEW)
- Jiang, Z., et al. "Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells." *Food Chem. Toxicol.* 2021; 147: 111919. (IVT, NEW)
- Bi, J., et al. "MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy." *Gynecol. Oncol.* 2019; 155: 349-358. (IVT, IVA, NEW)
- Zhang, Y., et al. "Pristimerin enhances the effect of cisplatin by inhibiting the miR 23a/Akt/GSK3 β signaling pathway and suppressing autophagy in lung cancer cells." *Int. J. Mol. Med.* 2019 Mar; 43(3): 1382-1394. (IVT, IVA, NEW)
- Lee, Y., et al. "Combination of pristimerin and paclitaxel additively induces autophagy in human breast cancer cells via ERK1/2 regulation." *Mol. Med. Rep.* 2018 Nov; 18(5): 4281-4288. (IVT, NEW)
- Yan, Y., et al. "Degradation of P-glycoprotein by pristimerin contributes to overcoming ABCB1-mediated chemotherapeutic drug resistance *in vitro*." *Oncol. Rep.* 2017 Jan; 37(1): 31-40. (IVT, NEW)
- Xie, G., et al. "Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling." *Oncol. Lett.* 2016 May; 11(5): 3111-3116. (IVT, NEW)
- Xie, G., et al. "Inhibitory effect of pristimerin on growth of taxol-resistant breast cancer cells." *J. Guizhou Med. Univ.* 2016; 41(09): 1029-1032. (IVT, NEW)
- Wang, Y., et al. "Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells." *PLoS One.* 2012; 7(8): e43826. (IVT, NEW)
- Eum D., et al. "Triterpenoid pristimerin synergizes with taxol to induce cervical cancer cell death through reactive oxygen species-mediated mitochondrial dysfunction." *Anticancer Drugs.* 2011; 22: 763-773. (IVA, NEW)

Immune Modulation:

- Liu, Y., et al. "Anticancer agent pristimerin inhibits IL-2 induced activation of T lymphocytes." *J. Exp. Ther. Oncol.* 2016 Jul; 11(3): 181-188. (IVT, NEW)

Hui, B., et al. "Pristimerin, a natural anti-tumor triterpenoid, inhibits LPS-induced TNF- α and IL-8 production through down-regulation of ROS-related classical NF- κ B pathway in THP-1 cells." *Int. Immunopharmacol.* 2014 Aug; 21(2): 501-8. **(IVT, NEW)**

Cancer Drug Development:

Martin-Aubert, S., "Successful repositioning of mertansine for improved chemotherapy by combining a polymer prodrug approach and PET imaging." *J. Control Release.* 2024 Dec: S0168-3659. **(IVT, NEW)**

He, P., et al. "Celastrol-loaded hyaluronic acid/cancer cell membrane lipid nanoparticles for targeted hepatocellular carcinoma prevention." *Cells.* 2024 Nov; 13(21): 1819. **(IVT, IVA)**

Zhu, Y., et al. "Recent Trends in anti-tumor mechanisms and molecular targets of celastrol." *Int. J. Biol. Sci.* 2024 Oct; 20(14): 5510-5530. **(REV)**

Fu, X., et al. "Scaffold hopping of pristimerin provides derivatives containing a privileged quinoxaline substructure as potent autophagy inducers in breast cancer cells." *J. Nat. Prod.* 2024 Aug 23; 87(8): 1952-1964. **(IVT, NEW)**

Xu, C., et al. "ML385, an Nrf2 Inhibitor, synergically enhanced celastrol triggered endoplasmic reticulum stress in lung cancer cells." *ACS Omega.* 2024 Oct; 9(43): 43697-43705. **IVT**

Zafar, S., et al. "New insights into the anticancer therapeutic potential of maytansine and its derivatives." *Biomed. Pharmacother.* 2023 Sep; 165: 115039. **(REV)**

Wang, C., et al. "Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies." *Biomed. Pharmacother.* 2023 Jul; 163: 114882. **(REV)**

Tabernero, J., et al. "Tusamitamab ravtansine in patients with advanced solid tumors: Phase I study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens." *Cancer Res. Commun.* 2023 Aug 28; 3(8): 1662-1671. **(HS)**

Liu, C., et al. "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids." *Proc. Natl. Acad. Sci.* 1996 Aug; 93(16): 8618-23. **(IVA)**

Early Studies in the Development of a Maytansine and Maitenin Drugs:

Fox, B. W. "Medicinal plants in tropical medicine. 2. Natural products in cancer treatment from bench to the clinic." *Trans. R. Soc. Trop. Med. Hyg.* 1991; 85(1): 22-5. **(REV)**

Ravry, M. J., et al. "Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group Trial." *Am. J. Clin. Oncol.* 1985 Apr; 8(2): 148-50. **(HS)**

Suffnes, M., et al. "Current status of the NCI plant and animal product program." *J. Nat. Prod.* 1982; 45: 1-14. **(IVT, IVA)**

Cabanillas, F., et al. "Phase I study of maytansine using a 3-day schedule." *Cancer Treatment Reports.* 1976; (60): 1127-39. **(HS)**

Chabner, B. A., et al. "Initial clinical trials of maytansine, an antitumor plant alkaloid." *Cancer Treatment Reports.* 1978; (62): 429-33. **(HS)**

O'Connell, M. J., et al. "Phase II trial of maytansine in patients with advanced colorectal carcinoma." *Cancer Treat. Rep.* 1978 (62); 1237-38. **(HS)**

Monache, F. D., et al., "Maitenin: A new antitumoral substance from *Maytenus* sp." *Gazzetta Chimica Italiana* 1972; 102: 317-20. **(IVT, IVA)**

de Santana, C. F., et al. "[First observations on the use of maitenin in cancer patients.]" *Rev. Inst. Antibiot.* 1971; 11: 37-49. **(HS)**

Hartwell, J. "Plants used against cancer: A survey." *Lloydia.* 1968; 31: 114. **(REV)**

Safety/Toxicity Studies:

Danilevicz, C., et al. "Pharmacological evaluation of a traditional Brazilian medicinal plant, *Monteverdia ilicifolia*. Part I - Preclinical safety study." *J. Ethnopharmacol.* 2024 Apr; 324: 117806. (IVT)

do Nascimento, S., et al. "Validation of a HPLC method for quantification of midazolam in rat plasma: Application during a *Maytenus ilicifolia*-drug interaction study." *Biomed. Chromatogr.* 2021 Mar; 35(3): e4999. (IVT, NEW)

Tabach, R., et al. "Pharmacological and Toxicological study of *Maytenus ilicifolia* leaf extract Part II-clinical study (Phase I)." *Phytother. Res.* 2017 Jun; 31(6): 921-926. (HS)

Tabach, R., et al. "Pharmacological and toxicological study of *Maytenus ilicifolia* leaf extract. Part I - Preclinical studies." *Phytother. Res.* 2017 Jun; 31(6): 915-920. (IVA)

Ecker, A., et al. "Safety evaluation of suprathreshold dose of *Maytenus ilicifolia* Mart. ex Reissek extracts on fertility and neurobehavioral status of male and pregnant rats." *Regul. Toxicol. Pharmacol.* 2017 Nov; 90: 160-169. (IVA)

Cunha-Laura, A., et al. "Effects of *Maytenus ilicifolia* on reproduction and embryo-fetal development in Wistar rats." *Genet. Mol. Res.* 2014 May; 13(2): 3711-20. (IVA)

Horn, R., et al. "Antimutagenic activity of extracts of natural substances in the Salmonella/microsome assay." *Mutagenesis.* 2003 Mar; 18(2): 113-8. (IVT)

Oliveira, M., et al. "Pharmacologic and toxicologic effects of two *Maytenus* species in laboratory animals." *J. Ethnopharmacol.* 1991 Aug; 34(1): 29-41. (IVA)

[Return to the Espinheira Santa plant database file](#)

Return to [Fighting Cancer with Plants from the Rainforest](#), by Leslie Taylor

© Copyrighted 2025 by Leslie Taylor. All rights reserved.